Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027613 | 1.00 | FOLH1 (0.46) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL7027611 | 1.00 | FOLH1 (0.46) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL1413149 | 0.94 | FOLH1 (0.53) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL209237 | 0.94 | FOLH1 (0.53) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL3727817 | 0.94 | FOLH1 (0.53) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL8191952 | 0.88 | GABRR1 (0.52) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL756912 | 0.88 | GABRR1 (0.52) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL4783069 | 0.86 | FOLH1 (0.45) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL4783065 | 0.86 | FOLH1 (0.45) | FOLH1GABRR1CPB2GSRRNPEP | |
| SCHEMBL8254457 | 0.86 | FOLH1 (0.45) | FOLH1GABRR1CPB2GSRRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221277-A1 | Method For Elevating Prolactin In Mammals | CARA THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130012431-A1 | Method For Elevating Prolactin In Mammals | CARA THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8217000-B2 | Method for elevating prolactin in mammals | CARA THERAPEUTICS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100029575-A1 | N-Oxides of Kappa Receptor Peptides | CARA THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090312271-A1 | Method For Elevating Prolactin in Mammals | CARA THERAPEUTICS INC. (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101454017-A | Method for elevating prolactin in mammals | CARA THERAPEUTICS INC (US) | 2009-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029575-A1 | N-Oxides of Kappa Receptor Peptides | OPRD1, OPRK1, OPRM1 | FOLH1 3041/4885GABRR1 458/4885CPB2 2511/4885 |
| US-20130012431-A1 | Method For Elevating Prolactin In Mammals | PRLHR, OPRK1, OPRL1 | FOLH1 259/4885GABRR1 435/4885CPB2 302/4885 |
| US-20090312271-A1 | Method For Elevating Prolactin in Mammals | PRLHR, OPRK1, OPRL1 | FOLH1 259/4885GABRR1 435/4885CPB2 302/4885 |
| US-20140221277-A1 | Method For Elevating Prolactin In Mammals | PRLHR, OPRK1, OPRL1 | FOLH1 259/4885GABRR1 435/4885CPB2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.